Cash-sweep triggers, cure periods and release tests

A cash sweep is a set of conditions and cash instructions, not simply a ratio below a line. The entry test, exit test and treatment of accumulated funds may differ. A borrower should model the entire sequence before assuming that improved performance restores distributions.

Begin by extracting the exact metric, measurement period, calculation rules and decision authority. Then identify when a trigger takes effect, whether a cure requires consecutive periods, what other events prevent release and how the servicer confirms the change. Preserve the underlying calculations rather than recording only a pass or fail label.

Read entry and exit as separate tests

The May 18, 2023 Guggenheim agreement, Section 2.9, illustrates different performance conditions for initiating control and returning it to the borrower. The agreement also conditions release on other facts. This is one negotiated structure, not a universal rule.

In the actual documents, check whether the test uses historical, annualized or adjusted cash flow and which loan balance applies. Determine whether cash collateral changes the metric. A borrower should not subtract a reserve from debt unless the governing definition permits that treatment.

Identify the testing date separately from the reporting deadline and the servicer’s acceptance date. A quarter can finish before the necessary financial statements are available. The forecast should not treat a ratio calculated internally on the last day of the quarter as an effective release instruction.

Worked exhibit: a recovery that does not immediately cure

Assume an invented agreement starts a sweep when debt yield falls below 8.0%. Exit requires at least 8.5% for two consecutive quarters, no other disqualifying event and written confirmation. These thresholds are hypothetical. The loan balance remains $5,000,000, and each quarter’s figure below is already the annual cash flow specified by the invented test.

Q2’s improvement does not complete the cure. Q3 is above the entry threshold but below the exit threshold, so the sweep continues under these invented terms. The earliest performance-based cure is after Q5, subject to the other conditions and confirmation.

Do not characterize that outcome as a breach solely because the sweep remains active. A cash-management trigger and an event of default can be separate concepts. Read the documents to determine what each event means and what consequences follow.

Track retained cash independently

For this example, assume each quarter’s residual is available at quarter-end. The Q1 test and effective control instruction occur before that first residual would be distributed, and written release confirmation remains pending until after Q5’s residual is retained. Thus the model does not assume a quarter-end trigger retroactively trapped earlier distributions. Residuals retained for Q1 through Q5 are $25,000, $30,000, $28,000, $35,000 and $40,000. The accumulated balance is $158,000 before fees, interest or permitted uses. An internally forecasted cure does not turn that balance into an available source.

Assume, only for this example, that $20,000 is applied to an approved obligation while the sweep is active. The remaining retained balance is $138,000. If the agreement allows future receipts to return to ordinary accounts but requires a separate release decision for the accumulated balance, those are two different cash events.

A refinancing plan that counts the $138,000 at closing needs evidence that it will be released or credited on the required date. Otherwise, show a separate funding case without that source. The borrower can then identify whether a delayed release affects closing feasibility or only subsequent liquidity.

Test a paydown cure carefully

A lower balance can improve debt yield mathematically. At $420,000 of annual defined cash flow, an 8.5% ratio corresponds to debt of approximately $4,941,176.47. Relative to $5,000,000, that is a $58,823.53 reduction.

This calculation does not establish a contractual right to cure through paydown. The agreement may restrict the route, impose a minimum amount, preserve a consecutive-period requirement or require additional evidence. Label the arithmetic as a scenario and ask the authorized decision maker whether the proposed cure is recognized.

Also include payment premiums, fees and reserve effects when evaluating the cash cost. Principal reduction and total cash needed to implement a cure are different amounts.

Maintain a trigger and release record

For every test, retain the source financials, adjustments, balance confirmation, reviewer, submission date and accepted result. Track unrelated defaults or missing reports that could block an otherwise satisfied performance condition. Correct errors through a documented revision rather than overwriting the earlier calculation without explanation.

The useful conclusion is a dated state: not triggered, active sweep, qualifying cure period, awaiting confirmation or released. Attach the retained-cash balance and the next evidence requirement. That gives owners a realistic distribution forecast and prevents a single improved quarter from becoming an unsupported promise of cash access.